Compare ADMA Biologics Inc (ADMA) vs Bank of Montreal (BMO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Bank of Montreal — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while Bank of Montreal trades at $174.7 (market cap $124.94B). The key difference: Bank of Montreal is far larger — about 58.7× ADMA Biologics Inc's market cap, and Bank of Montreal pays a 2.78% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | BMO | |
|---|---|---|
Market Cap | $2.13B | $124.94B |
Sector | Health | Financials |
52-Week High | $20.38 | $178.25 |
52-Week Low | $7.60 | $110.44 |
Enterprise Value | $2.20B | — |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
BMO trades at $178.25, up 2.37% today, with a bullish technical signal and strong analyst support. Recent earnings show a mixed record with a Q1 2026 miss but beats in prior quarters, while revenue and net income have grown steadily. The company maintains a solid dividend history and was recently recognized as Best Commercial Bank in Canada and the U.S. by World Finance Magazine (June 23, 2026).
The outlook is positive given earnings growth and strategic acquisitions, but risks include valuation above historical averages and sensitivity to interest rates. Analyst consensus is evenly split between Buy and Hold, indicating cautious optimism for continued performance amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Bank of Montreal
Bank of Montreal is a diversified financial-services provider based in North America, operating four business segments: Canadian personal and commercial banking, U.S. P&C banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the U.S.
Read more on BMO →
